Academic medical centers

NIH is its own ecosystem: institutes with distinct priorities, mechanisms that reward very different framing, and study sections that decide the outcome.

An academic medical centre competes for federal funding on a scale and in a specificity that generalist advice does not reach. Which institute, which mechanism, which study section — those three decisions shape a submission more than anything in the science, and they interact. The same programme framed for one institute can be non-responsive at another. Our work is at that level of specificity, plus the translational question of what happens when research needs a commercial path.

What is different here

Institute and mechanism selection

NIH is not one funder. The institute, the activity code and the study section together determine who reads it and against what.

Multi-PI and centre awards

Large mechanisms need a governance and management plan that reviewers score, not just an aggregation of good investigators.

The translational gap

Research that needs a commercial path has options — SBIR, STTR, partnership, spin-out — with real consequences for institutional IP.

Resubmission strategy

A summary statement tells you whether the science or the framing was the problem. Those need very different responses.

Relevant practice areas

Federal Grant AdvisoryFederal grant strategy for research-driven organisations — programme selection, agency engagement and proposal positioning across NIH, DOE, NSF and DoD.Venture Capital AdvisoryEarly-stage advisory for research-driven ventures — academic spin-outs, translational research and companies bridging from grant funding to venture capital.Government RelationsGovernment relations and legislative advocacy from Washington — agency engagement, appropriations monitoring and representation before Congress.

Common questions

Do you advise on which NIH institute to approach?

Yes, and it is often the highest-leverage decision in the whole process. Institute priorities shift, and the same work can be central to one portfolio and peripheral to another.

What about translational work heading toward a company?

That is where the grant and capital practices meet. The sequence — what to prove with non-dilutive funding before raising — materially changes the terms available later, and the institution's IP position has to be settled first.

Can you help after an unsuccessful submission?

Yes. Reading a summary statement honestly is a skill: it usually distinguishes a fixable framing problem from a fundamental one, and resubmitting against the wrong reading wastes a cycle.